P2X7 systemic blockade activated an ICD–like mechanism in cancer cells leading to tumor growth reduction and activation of antitumor responses while reducing the tumor-promoting inflammatory cytokine IL-1β (De Marchi et al., 2019). Here, P2RX7 is linked to cancer.